Himisha Beltran, M.D.

Himisha Beltran

I am a medical oncologist specializing in the treatment of patients with genitourinary malignancies (including prostate, bladder, testes, and kidney cancers). My clinical and translational research focuses on development of new treatment strategies for patients. In particular, I am studying the genetics of prostate cancer, and I am involved in developing personalized treatment approaches for patients based on their cancer's specific molecular alterations. My clinical practice and research rely on close collaborations with clinicians, scientists, and physician scientists from multiple disciplines including pathology, urology, radiology, radiation oncology, computational biology, pharmacology, and medical oncology.

Dr. Himisha Beltran joined the Division as Assistant Professor of Medicine in 2011. Her clinical focus is in caring for patients with genitourinary malignancies (prostate cancer, bladder cancer, germ cell tumor, kidney cancer). She is actively involved in both laboratory-based and clinical research, and she serves as the liason for several bench-to-bedside translational research efforts at Weill Cornell. Dr. Beltran is involved in developing a research program to study neuroendocrine prostate cancer, an aggressive subtype of prostate cancer. By studying the RNA and DNA of these tumors, she is learning how these cancers evolve, identifying molecular alterations to target with drugs, and developing clinical trials to bring new effective therapy to patients. She is also involved in writing and leading several genitourinary clinical trials at Weill Cornell, and participates in national and international trials through the Alliance for Clinical Trials in Oncology Foundation and National Cancer Institute (NCI). Dr. Beltran is the recipient of numerous awards, including a Prostate Cancer Foundation Young Investigator Award, AACR Women in Cancer Research Scholar Award, and Damon Runyon Cancer Research Foundation Clinical Investigator Award.




Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]


Galletti G, Matov A, Beltran H, Fontugne J, Mosquera JM, Cheung C, MacDonald TY, Sung M, O’Toole S, Kenc JG, Chae SS, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS, ERG Induces Taxane Resistance in Castration-Resistant Prostate Cancer, Nature Communications, In Press.

Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Park K, Kossai M, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran HFox AH, Elemento O, Rubin MA. The Estrogen receptor alpha regulated NEAT1 long non-coding RNA promotes prostate cancer progression. Nature Communications, In Press.

Gao D ,Vela I, Sboner A, Iaquinta PJ, Karthaus WP, Gopalan A, Wajala JN, Dowling C, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis K, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, James A. Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL,Chen Y. Generation of in vitro organoid cultures derived from patients with advanced prostate cancer. Cell, 2014 Sep 3. S0092-8674(14)01047-2 [Epub ahead of print]

 Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera JM, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F, Unraveling the clonal hierarchy of somatic genomic aberrations, Genome Biology, 2014 Aug 26;15(8):439. [Epub ahead of print]

Himisha Beltran, Scott Tomlins, Ana Aparicio, Vivek Arora, David Rickman, Gustavo Ayala, Jiaoti Huang, Lawrence True, Martin E. Gleave, Howard Soule, Christopher Logothetis, Mark A. Rubin, Aggressive Variants of Prostate Cancer.  Clinical Cancer Research, 2014 Jun 1;20(11):2846-50.

Epstein J*, Amin M*, Beltran H, Lotan T, Mosquera JM, Reuter V, Robinson B, Troncoso P, Rubin MA. Proposed Morphologic Classification of Prostate cancer with Neuroendocrine Differentiation, American Journal of Surgical Pathology. 2014 Jun;38(6):756-67.

Park K, Chen Z, MacDonald T, Siddiqui J, Ye H, Erbersdobler A, Shevchuk MM,. Robinson BD, Chinnaiyan AM, Beltran H, Rubin MA, Mosquera JM. Prostate Cancer with Paneth Cell-like Neuroendocrine Differentiation has Distinct Histomorphology and Harbors AURKA Gene Amplification. Human Pathology, 2014 Jun;38(6):756-67. 

Himisha Beltran. N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential, Molecular Cancer Research, 2014 June; 12(6):815-2.

Stephane Terry and Himisha Beltran. The many faces of neuroendocrine differentiation in prostate cancer progression. Front. Oncol., 2014 March 25; 4:60.

Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Cull A, Fazli L, Sharma M, Beltran H, Rubin MA, Cox ME, Gout PW, Morris J, Goldenberg L, Volik SV, Gleave ME, Collins CC, Wang Y. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Research. 2014 Feb 15;74(4):1272-83

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J,  Sun J, White J, Sanford EM, An P, Juhn F, Brennan K, Kwanik K, Maillet A, Buell J, White E, Zhao M, Balasubramanian S, Terzic S, Richards T, Banning V, Garcia L, Mahoney K, Zwirko Z, Donahoue A, Schnall-Levin M,  Beltran H, Mosquera JM, Rubin MA, Dogan S, Hedvat CV, Berger MF, Pusztai L, Lechner M, Boshoff C, Jarosz M, Vietz C, Parker A, Miller VA, Ross JS, Curran J, Cronin MT,  Stephens PJ, Lipson D, Yelensky R. Validation and clinical application of a cancer genomic profiling test using next-generation sequencing. Nature Biotechnol. 2013 Nov;31(11):1023-31

Himisha Beltran. DNA Mismatch Repair in Prostate Cancer. Journal of Clinical Oncology, 2013 May 10; 31(14): 1782-1784.

Baca S, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA. Punctuated Evolution of Prostate Cancer Genomes. Cell, 2013 Apr 25;153(3):666-77.

Lin P, Giannopoulou E, Park K, Mosquera JM, Sboner A, Beltran H, Elemento O, Rubin MA. Epigenomic alterations in indolent and aggressive prostate cancer. Neoplasia, 2013 Apr;15(4):373-83.

Himisha Beltran and Mark A Rubin.  New Strategies in Prostate Cancer: Translating Genomics into the Clinic, Clinical Cancer Research, February 1, 2013 19; p517.

Juan Miguel Mosquera*, Himisha Beltran* (Co-First Author), Kyung Park, Theresa Y. MacDonald, Brian D. Robinson, Scott T. Tagawa, Sven Perner, Tarek A. Bismar, Andreas Erbersdobler, Rajiv Dhir, Joel B. Nelson, David M. Nanus, Mark A. Rubin. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment related neuroendocrine prostate cancer. Neoplasia, Vol 15 (1) 1-10. January 2013.

Himisha Beltran, Scott T Tagawa, Kyung Park, Matthew M Milowsky, Juan Miguel Mosquera, Mark A Rubin, David M Nanus. Challenges in Recognizing Treatment Related Neuroendocrine Prostate Cancer. Journal of Clinical Oncology, Vol 30(36)386-89, Dec 20 2012.

Himisha Beltran, Roman Yelensky*, Garrett M. Frampton, Kyung Park, Sean R. Downing, Theresa Y. MacDonald, Mirna Jarosz, Doron Lipson, Scott T. Tagawa, David M. Nanus, Philip J. Stephens, Juan Miguel Mosquera, Maureen T. Cronin, Mark A. Rubin. Targeted Next Generation Sequencing of Advanced Prostate Cancer Identifies New Therapeutic Targets and Disease Heterogeneity, European Urology, 2013 May;63(5):920-6.

Lin P, Chiu Y, Banerjee S, Park K, Mosquera JM, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H, Melnick AM, Elemento O, Demichelis F, Rubin MA. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Research, 2013 Feb 1;73(3):1232-1244.

Terry S, Maillé P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y, de la Taille A, Vacherot F. Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer. Neoplasia, In Press.

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JH ,Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N, Stenzel B, Schaefer G, Horninger W, Bektic J, Chinnaiyan AM, Goldenberg S, Siddiqui J, Regan MM, Kearney M, Soong TD, Rickman DS, Elemento O, Wei JT, Scherr DS, Sanda MA, Bartsch G, Lee C, Klocker H, Rubin MA. Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proceedings of the National Acadamy of Science (PNAS), 2012 Apr 24; 109 (17):6686-91.

Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajiresouliha I, Boutros PC, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012 May 3. doi: 10.1002/path.4047.

Collins CC, Volik SV, Lapuk A, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demichelis F, Beltran H, Hirst M, Marra MA, Maher CA, Chinnaiyan AM, Gleave ME, Bertino JR, Lubin M, Wang Y. Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenine Phosphorylase (MTAP), an Exploitable Tumor Target. Mol Cancer Ther. 2012 March; 11(3)775-83.

Himisha Beltran, David S. Rickman*, Kyung Park, Sung Suk Chae, Andrea Sboner, Theresa Y. MacDonald, Yuwei Wang, Karen L. Sheikh, Stéphane Terry, Scott T Tagawa, Rajiv Dhir, Joel B. Nelson, Alexandre de la Taille, Yves Allory, Mark B. Gerstein, Sven Perner, Kenneth J. Pienta, Arul M. Chinnaiyan, Yuzhuo Wang, Colin C. Collins, Martin E. Gleave, Francesca Demichelis, David M. Nanus, Mark A. Rubin. Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, November 17, 2011, 1:487-495.

Himisha Beltran, Tomasz Beer, Michael A Carducci, Johann de Bono, Martin Gleave, Maha Hussain, William K Kelly, Fred Saad, Cora Sternberg, Scott T Tagawa, Ian F Tannock. Therapies for castration-resistant prostate cancer: efficacy and safety. European Urology, August 2011. Vol 60: p 279–290.

Daniel J. Lee, Eugene K. Cha, Justin M. Dubin, Himisha Beltran, Douglas S. Scherr, Scott T. Tagawa, Shahrokh F. Shariat, Novel Therapeutics for the Management of Castration-Resistant Prostate Cancer. British Journal of Urology International (BJUI), 2012 Apr; 109(7): 968-85.

Scott T Tagawa and Himisha Beltran. Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. Asian Journal of Andrology, November 2011. Vol 13(6):785-6..

Himisha Beltran, Brian D Robinson, Scott T Tagawa. Primary Squamous Cell Carcinoma of the Urinary Bladder Presenting as Peritoneal Carcinomatosis. Advances in Urology, vol. July 2010. Article ID 179250.

Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith S, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus D, Bander N. Anti-Prostate Specific Membrane Antigen-based Radioimmunotherapy for Prostate Cancer. Cancer, February, 2010. Vol 116, p1075-1083.

Himisha Patel, Dan Vogl, Nicole Aqui, Edward A. Stadtmauer, Kim Otloff, Donald E. Tsai. Posttransplant Lymphoproliferative Disorder in Liver Transplant Recipients: A Report of Seventeen Cases. Leukemia and Lymphoma, May 2007. 48(5): 885-891.

Paul Kaplan, Himisha Patel, Douglas Austin. Assessing the risk of multiple gestation in gonadotropin intrauterine insemination cycles. American Journal of Obstetrics and Gynecology, June 2002. p 1245-1249.


Himisha Beltran, Juan Miguel Mosquera, Mark A Rubin. Neuroendocrine Prostate Cancer. The Comprehensive Textbook of Prostate Cancer (A. Tewari, Editor), Chapter 22, In Press

Himisha Beltran and Scott T Tagawa. Overview of disease pathways and drug targets. Targeted Therapies for Castration-Resistant Prostate Cancer (P. Scardino, Editor), Chapter 1, In Press

Scott T Tagawa, Naveed H Akhtar, Brian R Robinson, Himisha Beltran. Uncommon Cancers of the Prostate. Textbook of Uncommon Cancers, 4th Ed. (D. Raghavan , Editor). Wiley & Sons, Ltd, 2012.

Honors and Awards

The Alliance for Clinical Trials in Oncology Foundation Clinical Scholar Award In Honor of Dr. Emil “Tom” Frei III, 2014

Damon Runyon Cancer Research Foundation Clinical Investigator Award, 2013

21st Annual Department of Medicine Investigator Award, First Place. Weill Cornell Medical College, 2012

Scott Wadler Memorial Clinical Research Award, Weill Cornell Medical College, 2011

American Association for Cancer Research (AACR) Women in Cancer Research Scholar Award, 2011

Department of Medicine Fellows Research Award, First Place. Weill Cornell Medical College, 2011

American Society of Clinical Oncology (ASCO) Merit Awards, 2011, 2011, 2010

Prostate Cancer Foundation Young Investigator Award, 2010-13

Scholarship to attend ASCO- AACR Methods in Clinical Oncology Workshop, Vail, CO, 2010

CARE Award for Outstanding Service. "Resident/Fellow of The Month" for December, 2010. New York Presbyterian Hospital

Department of Medicine Fellows Research Award, Runner-Up. Weill Cornell Medical College, 2010

Ann and William Bresnan Fellowship in Hematology and Medical Oncology, 2009-10

Glasgow- Rubin Achievement Award, American Medical Women's Association, 2004

Merck Award for Academic Excellence, 2004

Alpha Omega Alpha Medical Honor Society (early induction), 2003

Phi Beta Kappa Academic Honor Society, 1999